Trial Profile
A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With Metastatic Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pelitrexol (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 15 May 2012 New trial record